Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation.
In a double-blind controlled study, oral acyclovir has been compared to a placebo in a series of 39 consecutive patients undergoing bone marrow transplantation. A dose of 200 mg was given every 6 h from day 8 to day 35 after transplantation. Pharmacokinetic studies have shown the good absorption of the drug despite intestinal damage related to chemoradiotherapy or gut graft-versus-host disease (GVHD); there was no sign of toxicity. The protection against herpes simplex virus (HSV) infection was complete in the treated group when compared to the control group even in patients with high anti-HSV antibody titres. The same protection was observed against cytomegalovirus (CMV) infection. The incidence of HSV and CMV was the same in both groups after treatment ended. This study confirms the efficacy of acyclovir against HSV infection and possibly against CMV infection when it is given prophylactically after bone marrow transplantation.
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006086:Graft vs Host Disease / Q000517:prevention & control; D006561:Herpes Simplex / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy; D007408:Intestinal Absorption; D007938:Leukemia / Q000628:therapy; D011897:Random Allocation; D012008:Recurrence
D000212:Acyclovir